CMS Official Says Revamped CED Program Could Benefit Molecular Dx Reimbursement
November 16, 2011
CMS Official Says Revamped CED Program Could Benefit Molecular Dx Reimbursement
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform
March 14, 2012 / Pharmacogenomics Reporter - Avalere Predicts Genomic Medicine Interventions will be Subject of CMS National Coverage Decisions
January 25, 2012 / Pharmacogenomics Reporter - FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says
December 7, 2011 / Pharmacogenomics Reporter - Palmetto Issuing 'Z-Codes' to Track Molecular Dx Utilization, Gather Data CPT Codes Can't Provide
November 16, 2011 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter